Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia

Summary

The purpose of this study is to see what dose of 225Ac-lintuzumab is safest to give to acute myeloid leukemia (AML) patients who are in remission but still have minimal residual disease (MRD). About 12 subjects will be asked to take part in this phase 1, 3+3 dose-escalation study. In addition to confirming the safety profile of postremission therapy with 225Ac-lintuzumab, preliminary evidence of efficacy will be assessed by estimating progression-free survival (PFS) and overall survival (OS), and serially evaluating for MRD using cytogenetics, fluorescence in situ hybridization (FISH), or flow cytometric assays, as applicable.

Timeline

Start

2019-02-28

Primary completion

2019-02-28

Completion

2019-02-28

Outcome

Outcome not reported

Stopped: “Due to difficulty in finalizing the contract”

Drugs

Indications